ISA Pharmaceuticals Promotes Gerben Moolhuizen to Chief Executive Officer

Leiden, The Netherlands, May 23, 2018 - ISA Pharmaceuticals B.V., a clinical-stage immune oncology company, today announced that Gerben Moolhuizen has been promoted from Chief Business Officer to Chief Executive Officer, effective June 1, 2018. He takes over the position from Ronald Loggers, who has served as ISA Pharmaceuticals´ CEO since 2013.

"We would like to thank Ronald Loggers for his leadership during the past five years and his contribution in developing ISA Pharmaceuticals into a leading European immuno-oncology player," said Bart Bergstein, Chairman of ISA´s Board of Directors. "We look forward to further advancing ISA´s pipeline and commercial reach and are delighted that Gerben Moolhuizen, who played a key role in closing ISA´s latest deal with Regeneron, will take over as CEO."

With over twenty years of experience in the pharmaceutical and biotechnology industry, Gerben Moolhuizen has a strong track record in various management roles covering business development, product development and general management. His experience spans diverse fields and a broad array of technologies (biopharmaceuticals, small molecules, drug delivery, pharmaceutical development and manufacturing, diagnostics, vaccines, and generics). From January 2016 to May 2018, Gerben Moolhuizen served as ISA Pharmaceuticals´ Chief Business Officer (CBO).

"I am excited about my appointment as ISA´s CEO," said Gerben Moolhuizen. "Over the last years, ISA has significantly matured to a company with strong clinical data and respected pharma partners. We are now looking forward to further advancing our clinical pipeline and to pursuing new business opportunities."

Gerben Moolhuizen holds an M.Sc. from Utrecht University in Medical Biology and an MBA from Erasmus University Rotterdam. Prior to his involvement with ISA Pharmaceuticals, he was General Manager at OctoPlus B.V. and has been closely involved in the company´s fundraising activities, its IPO, and the acquisition by Dr. Reddy's. Moreover, he has also been responsible for the subsequent integration of OctoPlus into Dr. Reddy's R&D organization. Prior to OctoPlus, Gerben Moolhuizen worked, among others, at Pharming N.V., where he held various roles in business development and product development.

###

About ISA Pharmaceuticals

ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT® technology. SLP® immunotherapies are designed to fully harness and direct the body´s own defenses towards fighting the disease. In December 2017, ISA Pharmaceuticals closed a clinical immuno-oncology collaboration with Regeneron to advance its SLP® lead compound ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with Cemiplimab (REGN2810), a PD-1 (programmed cell death protein 1) antibody. In addition, ISA develops on-demand personalized SLP® immunotherapies targeting orphan diseases and patient-specific, mutation-derived tumor neo-antigens (MyISA®).
For more information, please visit www.isa-pharma.com.

SLP®, AMPLIVANT® and MyISA® are registered trademarks in Europe.

ISA Pharmaceuticals B.V.
J.H. Oortweg 19
2333 CH Leiden
The Netherlands
T: +31 71 33 22 310
F: +31 71 33 22 311
E: info@isa-pharma.com

Contact & Media Inquiries:
akampion
Dr. Ludger Wess, Ines-Regina Buth
Managing Partners
Tel. +49 40 88 16 59 64, +49 30 23 63 27 68
info(at)akampion.com

This release was published on openPR.